Teva Pharma (NYSE: TEVA) reported Q4 EPS of $0.77, $0.04 better than the analyst estimate of $0.73. Revenue for the quarter came in at $4.1 billion versus the consensus estimate of $4.29 billion.

GUIDANCE:

Teva Pharma sees Q1 2022 EPS of $2.40-$2.60, versus the consensus of $2.64. Teva Pharma sees Q1 2022 revenue of $15.6-16.2 billion, versus the consensus of $16.32 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.